본문으로 건너뛰기
← 뒤로

Self-help cognitive behavioural therapy for hot flushes and night sweats during androgen deprivation therapy for prostate cancer: the MANCAN2 randomized controlled trial.

무작위 임상시험 1/5 보강
British journal of cancer 📖 저널 OA 88.3% 2022: 1/1 OA 2024: 11/11 OA 2025: 63/63 OA 2026: 98/123 OA 2022~2026 2026
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
162 patients were randomised.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] The addition of CBT in prostate cancer patients receiving ADT improved short-term HFNS severity, in addition to improved anxiety and depression scores, but these were not maintained at 6 months. [CLINICAL TRIAL REGISTRATION] ISRCTN58720120.

Crabb SJ, Morgan A, Stefanopoulou E, Fleure L, Griffiths GO, Boxall C, Wilding S, Nearchou T, Ewings S, Nuttall J, Eminton Z, Tilt E, Whitby E, Siu B, Ridley P, Robson L, Nobes J, Preece J, Bacon R, Martin J, Chamberlain S, Fenlon D, Hunter M, Richardson A

ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.9%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도

📝 환자 설명용 한 줄

[BACKGROUND] Androgen deprivation therapy (ADT) causes hot flushes and night sweats (HFNS) and is associated with sleep disturbance, anxiety, low mood and cognitive impairment.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value p = 0.03

이 논문을 인용하기

↓ .bib ↓ .ris
APA Crabb SJ, Morgan A, et al. (2026). Self-help cognitive behavioural therapy for hot flushes and night sweats during androgen deprivation therapy for prostate cancer: the MANCAN2 randomized controlled trial.. British journal of cancer. https://doi.org/10.1038/s41416-026-03375-4
MLA Crabb SJ, et al.. "Self-help cognitive behavioural therapy for hot flushes and night sweats during androgen deprivation therapy for prostate cancer: the MANCAN2 randomized controlled trial.." British journal of cancer, 2026.
PMID 41872531 ↗

Abstract

[BACKGROUND] Androgen deprivation therapy (ADT) causes hot flushes and night sweats (HFNS) and is associated with sleep disturbance, anxiety, low mood and cognitive impairment. We tested self-help cognitive behavioural therapy (CBT), when guided by prostate cancer nurse specialist teams, for mitigation of the long-term impact of HFNS, and associated symptoms.

[METHODS] Prostate cancer patients receiving ADT, with a HFNS Problem Rating Scale ≥2, were randomised (1:1) to treatment as usual (TAU) or CBT + TAU, stratified by centre and treatment intent. CBT was a 4-week self-help intervention with pre- and post-intervention group workshops guided by trained prostate cancer nurse specialists.

[PRIMARY ENDPOINT] 6-month HFNS Problem Rating Scale. Secondary endpoints included HFNS frequency, ADT compliance and rating scales for HFNS beliefs and behaviours, quality of life, anxiety, depression and sleep.

[RESULTS] 162 patients were randomised. 6 month mean HFNS Problem Rating Scale score was not significantly different between the TAU and CBT + TAU groups (mean 4.08 vs 4.04, 95% confidence interval (CI) for difference: -0.89, 0.80; p = 0.97), although was improved at 6 weeks (mean 4.47 vs 3.79, 95% CI: -1.26, -0.09; p = 0.03), when depression, anxiety scores and ADT compliance also favoured CBT + TAU.

[CONCLUSIONS] The addition of CBT in prostate cancer patients receiving ADT improved short-term HFNS severity, in addition to improved anxiety and depression scores, but these were not maintained at 6 months.

[CLINICAL TRIAL REGISTRATION] ISRCTN58720120.